Beta Bionics, Inc. Common Stock BBNX Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $27.63M+56.6% | $32.12M+57.1% | $27.25M+63.1% | $23.24M+54.4% | $17.64M+36.4% | ||
| $11.19M+29.1% | $13.18M+50.6% | $12.13M+55.7% | $10.74M+54.2% | $8.67M+51.2% | ||
| $16.44M+83.2% | $18.94M+62.1% | $15.12M+69.6% | $12.5M+54.7% | $8.97M+24.6% | ||
| 59.5%+8.6pp | 59%+1.8pp | 55.5%+2.1pp | 53.8%+0.1pp | 50.9%-4.8pp | ||
| $10.36M+36.4% | $10.13M+10.0% | $8.2M+59.4% | $8.87M+39.7% | $7.59M+38.5% | ||
| $20.74M+54.7% | $16.33M+51.2% | $16.05M+66.4% | $15.62M+74.1% | $13.4M+74.9% | ||
| $9.62M+45.2% | $8.6M+82.7% | $7.92M+55.2% | $7.88M+73.4% | $6.62M+88.5% | ||
| $40.71M+47.4% | $35.07M+41.8% | $32.16M+61.7% | $32.38M+63.0% | $27.61M+65.8% | ||
| $40.71M+47.4% | $35.07M+41.8% | $32.16M+61.7% | $32.38M+63.0% | $27.61M+65.8% | ||
| -$24.27M-30.2% | -$16.12M-23.7% | -$17.04M-55.3% | -$19.87M-68.6% | -$18.64M-97.2% | ||
| -87.9%+17.8pp | -50.2%+13.6pp | -62.5%+3.2pp | -85.5%-7.2pp | -105.7%-32.6pp | ||
| $2.38M-2.5% | $2.66M+179% | $2.83M+243% | $3.01M+203% | $2.44M+114% | ||
| $2.38M+124% | —— | $2.83M+128% | $3M+212% | -$10.01M-234% | ||
| -$21.9M+23.6% | -$13.47M+25.6% | -$14.21M-45.9% | -$16.87M-16.6% | -$28.66M-130% | ||
| -79.3%+83.2pp | -41.9%+46.7pp | -52.1%+6.1pp | -72.6%+23.5pp | -162.5%-66.2pp | ||
| -$0.49+47.3% | -$0.29+89.4% | -$0.33+77.4% | -$0.39+83.5% | -$0.93+55.1% | ||
| -$0.49+47.3% | -$0.29+89.4% | -$0.33+77.4% | -$0.39+83.5% | -$0.93+55.1% | ||
| 44.4M+44.7% | 40.5M+537% | 43.6M+555% | 43.4M+611% | 30.7M+410% | ||
| 44.4M+44.7% | 40.5M+537% | 43.6M+555% | 43.4M+611% | 30.7M+410% | ||
| -$22.39M+21.4% | -$13.42M+25.9% | -$14M-45.0% | -$16.96M-17.1% | -$28.48M-126% | ||
| -$499K-385% | $49K— | $205K+159% | -$91K-250% | $175K+233% | ||
| $27.63M+56.6% | $32.12M+57.1% | $27.25M+63.1% | $23.24M+54.4% | $17.64M+36.4% | ||
| -$24.27M-30.2% | -$16.12M-23.7% | -$17.04M-55.3% | -$19.87M-68.6% | -$18.64M-97.2% | ||
| -$23.69M-29.2% | -$15.59M-21.7% | -$16.66M-56.5% | -$19.53M-70.0% | -$18.34M-100% | ||
| -$23.69M-29.2% | -$15.59M-21.7% | -$16.66M-56.5% | -$19.53M-70.0% | -$18.34M-100% | ||
| -85.7%+18.2pp | -48.5%+14.1pp | -61.1%+2.6pp | -84%-7.7pp | -104%-33.1pp | ||
| -$24.27M-30.2% | -$16.12M-23.7% | -$17.04M-55.3% | -$19.87M-68.6% | -$18.64M-97.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Beta Bionics, Inc. Common Stock's revenue?
- Beta Bionics, Inc. Common Stock (BBNX) generated $110.2M in revenue over the trailing twelve months, up 57.9% year over year.
- Is Beta Bionics, Inc. Common Stock profitable?
- Beta Bionics, Inc. Common Stock is not currently profitable: it reported a net loss of $66.4M over the trailing twelve months, a -60.3% net margin.
- What are Beta Bionics, Inc. Common Stock's profit margins?
- Gross margin is 57.2% and operating margin is -70.1%, with a -60.3% net margin.
- What is Beta Bionics, Inc. Common Stock's earnings per share?
- Beta Bionics, Inc. Common Stock's diluted EPS over the trailing twelve months is $-1.50.
- Where does Beta Bionics, Inc. Common Stock's income statement data come from?
- Every line is extracted from Beta Bionics, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
